DRAM2

Across TCGA pan-cancer cohorts, DRAM2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DRAM2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher DRAM2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DRAM2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, CCRCC, and LSCC are the cancer types where DRAM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	1.000	0.489	.038	12	view →
CCRCC	DFS	Median	II,III,IV	0.140	0.887	.038	6	view →
LSCC	OS	Median	All	0.879	0.743	.023	3	view →
UCEC	DFS	Median	All	0.938	1.000	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DRAM2–HNSC (OS)

Open the HNSC breakdown →